Streptozotocin-induced diabetes increases amyloid plaque deposition in AD transgenic mice through modulating AGEs/RAGE/NF-κB pathway

International Journal of Neuroscience

Volumn 124, Issue 8, 2014, Pages 601-608

  Wang, Xu ^a   Yu, Song ^a   Hu, Jiang Ping ^b   Wang, Chun Yan ^c   Wang, Yue ^a   Liu, Hai Xing ^a   Liu, Yu Li ^a  

^a LIAONING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b MUDANJIANG MEDICAL UNIVERSITY   (China)

^c JILIN MEDICAL COLLEGE   (China)

Author keywords

Advanced glycation end products; Alzheimer's disease; Diabetes mellitus; amyloid

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; SENILE PLAQUE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; BIOSYNTHESIS; COMPLICATION; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PATHOLOGY; PLAQUE, AMYLOID; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; GLYCOSYLATION END PRODUCTS, ADVANCED; MALE; MICE; MICE, TRANSGENIC; NF-KAPPA B; PLAQUE, AMYLOID; RECEPTORS, IMMUNOLOGIC;

EID: 84903852210     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2013.866110     Document Type: Article

References (35)

1. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61: 661-666
2. Cao D, Lu H, Lewis TL, Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 2007; 282: 36275-36282
3. WangX, ZhengW, Xie JW, Wang T, Wang SL, TengWP, Wang ZY. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener 2010; 5: 46-58
4. Burdo JR, Chen Q, Calcutt NA, Schubert D. The pathological interaction between diabetes and presymptomatic Alzheimer's disease. Neurobiol Aging 2009; 30: 1910-1917
5. Podell BK, Ackart DF, Kirk NM, Eck SP, Bell C, Basaraba RJ. Non-diabetic hyperglycemia exacerbates disease severity in Mycobacterium tuberculosis infected guinea pigs. PLoS One 2012; 7: E46824
6. Wada R, Nishizawa Y, Yagihashi N, Takeuchi M, Ishikawa Y, Yasumura K, Nakano M, Yagihashi S. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 2001; 31: 513-520
7. Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, Takeuchi M, Makita Z. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 2001; 888: 256-262
8. Alexiou P, Chatzopoulou M, Pegklidou K, Demopoulos VJ. RAGE: A multi-ligand receptor unveiling novel insights in health and disease. Curr Med Chem 2010; 17: 2232-2252
9. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9: 907-913
10. Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo Jr. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-Amyloid peptides. J Neurosci Res 2007; 85: 1194-1204
11. Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 2007; 56: 211-216
12. Kroner Z. The relationship between Alzheimer's disease and diabetes. Type 3 diabetes? Altern Med Rev 2009; 14: 373-379
13. Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, Zhang M, Yang Y, Cai F, Woodgett J, Song W. Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimerassociated phenotypes. J Clin Invest 2012; 123: 224-235
14. Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 2003; 23: 129-134
15. Munch G, Deuther-Conrad W, Gasic-Milenkovic J. Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer's disease-A target for neuroprotective treatment strategies? J Neural Transm Suppl 2002; 62: 303-307
16. Odetti P, Rossi S, Monacelli F, Poggi A, Cirnigliaro M, Federici M, Federici A. Advanced glycation end products and bone loss during aging. Ann N Y Acad Sci 2005; 1043: 710-717
17. Shuvaev VV, Laffont I, Serot JM, Fujii J, Taniguchi N, Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol Aging 2001; 22: 397-402
18. Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008; 14: 973-978
19. Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Munch G. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2009; 32: 763-777
20. Kuhla B, Loske C, Garcia De Arriba S, Schinzel R, Huber J, Munch G. Differential effects of Advanced glycation endproducts and beta-Amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y. J Neural Transm 2004; 111: 427-439
21. Loske C, Gerdemann A, Schepl W, Wycislo M, Schinzel R, Palm D, Riederer P, Munch G. Transition metal-mediated glycoxidation accelerates cross-linking of beta-Amyloid peptide. Eur J Biochem 2000; 267: 4171-4178
22. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: A fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 2010; 106: 842-853
23. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier. implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 2009; 8: 16-30
24. Lue LF, Walker DG, Jacobson S, Sabbagh M. Receptor for advanced glycation end products. its role in Alzheimer's disease and other neurological diseases. Future Neurol 2009; 4: 167-177
25. Yan SD, Bierhaus A, Nawroth PP, Stern DM. RAGE and Alzheimer's disease. a progression factor for amyloidbeta-induced cellular perturbation? J Alzheimers Dis 2009; 16: 833-843
26. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997; 272: 16498-16506
27. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274: 19919-19924
28. Kabe Y, Ando K, Hirao S, Yoshida M, Handa H. Redox regulation of NF-kappaB activation. distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal 2005; 7: 395-403
29. Smale ST. Hierarchies of NF-kappaB target-gene regulation. Nat Immunol 2011; 12: 689-694
30. Kaltschmidt B, Ndiaye D, KorteM, Pothion S, Arbibe L, Prullage M, Pfeiffer J, Lindecke A, Staiger V, Israel A, Kaltschmidt C, Memet S. NF-kappaB regulates spatial memory formation and synaptic plasticity through protein kinase A/CREB signaling. Mol Cell Biol 2006; 26: 2936-2946
31. Guglielmotto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, Catalano MG, Smith MA, Perry G, Danni O, Boccuzzi G, Tabaton M. AGEs/RAGE complex upregulates BACE1 viaNF-kappaB pathway activation.Neurobiol Aging 2010; 33: 196 e113-127
32. Chen CH, Zhou W, Liu S, Deng Y, Cai F, Tone M, Tone Y, Tong Y, Song W. Increased NF-kappaB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease. Int J Neuropsychopharmacol 2011; 1-14
33. Chami L, Buggia-Prevot V, Duplan E, Delprete D, Chami M, Peyron JF, Checler F. Nuclear factor-kappaB regulates betaAPP and beta-And gamma-secretases differently at physiological and supraphysiological Abeta concentrations. J Biol Chem 2012; 287: 24573-24584
34. Zhou W, Cai F, Li Y, Yang GS, O'Connor KD, Holt RA, Song W. BACE1 gene promoter single-nucleotide polymorphisms in Alzheimer's disease. J Mol Neurosci 2010; 42: 127-133
35. Cho HJ, Son SM, Jin SM, Hong HS, Shin DH, Kim SJ, Huh K, Mook-Jung I. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J 2009; 23: 2639-2649